Idiopathic Pulmonary Fibrosis

June 23, 2016June 23, 2016

Phase 2 Study of Hemoglobin Modifier, GBT440, to Treat IPF Getting Underway

Global Blood Therapeutics (GBT) is starting a Phase 2a clinical trial to assess the company’s lead product, GBT440, as a treatment for adults with idiopathic pulmonary fibrosis (IPF) and hypoxemia. GBT440 is ... Read more

June 22, 2016June 22, 2016

INOpulse Devices for PAH Disorders Evaluated in Clinical Trials

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Bellerophon Therapeutics recently enrolled the first participants in the Phase 3 INOvation-1 clinical trial intended to test the efficiency and safety of INOpulse for the treatment of pulmonary arterial hypertension (PAH). ... Read more

June 14, 2016June 14, 2016

Boehringer Ingelheim, Harvard Scientists Partner to Develop Novel Treatments for IPF, Other Fibrotic Diseases

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim and Harvard Stem Cell Institute’s (HSCI) Harvard Fibrosis Network recently announced a new research partnership to find novel treatments for fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), chronic kidney ... Read more

June 5, 2016June 6, 2016

Phase 2 Study of Molecule Inhibitor for Idiopathic Pulmonary Fibrosis Begins

Idiopathic Pulmonary Fibrosis

Kadmon Corporation, which develops first-in-class, innovative therapies against autoimmune and fibrotic diseases, oncology and genetic diseases, recently dosed the first patient in a Phase 2 clinical study of the company’s drug ... Read more

June 3, 2016June 6, 2016

Boehringer, Inventiva Form $190M IPF Research and Development Pact

Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim and Dijon, France-based Inventiva Pharma, a biopharma specializing in the development of innovative therapies for fibrosis, have announced the establishment of an idiopathic pulmonary fibrosis (IPF) research and development ... Read more

May 19, 2016May 19, 2016

Veracyte Shows New Drug Data for IPF Diagnosis at ATS 2016

Idiopathic Pulmonary Fibrosis, News

Veracyte presented data at the recent American Thoracic Society (ATS) 2016 International Conference from a study proving the potential of its Envisia classifier to improve the diagnosis of interstitial lung diseases, ... Read more

May 19, 2016May 19, 2016

Afferent Presents Promising Data from Phase 2 Study in People with Chronic Cough

Idiopathic Pulmonary Fibrosis, News

Afferent Pharmaceuticals announced positive results from a Phase 2 clinical trial of its candidate AF-219, a selective oral P2X3 antagonist, for the treatment of chronic cough. Data from the first cohort ... Read more

May 18, 2016May 18, 2016

Efficacy and Safety of Ofev (Nintedanib) as IPF Treatment Supported by New Analyses

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals presented 12 idiopathic pulmonary fibrosis (IPF)-related abstracts at the recent American Thoracic Society (ATS) 2016 Annual Conference, including further analyses of its INPULSIS clinical trial program, which added to the ... Read more

May 13, 2016May 13, 2016

ATS 2016 International Conference Features Keynote Series

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

The American Thoracic Society (ATS) is hosting the ATS 2016 International Conference through May 18 in San Franscico, Calif. This year’s conference will feature the ATS Keynote Series with eight ... Read more

May 12, 2016May 13, 2016

Veracyte to Show Data on Lung Disease Genomic Classifiers at ATS 2016

Idiopathic Pulmonary Fibrosis, Lung Cancer, News

Veracyte, Inc. will present results at the American Thoracic Society (ATS) 2016 International Conference from multiple trials supporting the company’s genomic tests that may resolve uncertainty in lung disease diagnosis. The company ... Read more